×
About 19,658 results

ALLMedicine™ Acute Lymphoblastic Leukemia Center

Research & Reviews  6,538 results

Exploiting Natural Killer cell engagers to control pediatric B-cell precursor acute lym...
https://doi.org/10.1158/2326-6066.CIR-21-0843
Cancer Immunology Research; Colomar-Carando N, Gauthier L et. al.

Jan 27th, 2022 - Natural killer (NK) cells represent a promising cell type in antitumor immunotherapy for efficacy and safety, particularly in the treatment of hematological malignancies. NK cells have been shown to exert anti-leukemia activity in the context of h...

Ixazomib in addition to chemotherapy for the treatment of acute lymphoblastic leukemia ...
https://doi.org/10.1080/10428194.2021.2018582
Leukemia & Lymphoma; Amrein P, Ballen K et. al.

Jan 26th, 2022 - We sought to assess the safety of adding ixazomib, an oral proteasome inhibitor, to a multi-agent treatment regimen for older adults with acute lymphoblastic leukemia (ALL). Patients 51 to 75 years of age with newly diagnosed ALL were screened. In...

Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeut...
https://doi.org/10.1186/s13045-022-01228-0
Journal of Hematology & Oncology; Padella A, Ghelli Luserna Di Rorà A et. al.

Jan 24th, 2022 - The members of the Poly(ADP-ribose) polymerase (PARP) superfamily are involved in several biological processes and, in particular, in the DNA damage response (DDR). The most studied members, PARP1, PARP2 and PARP3, act as sensors of DNA damages, i...

Lymphoblastic Lymphoma: a Concise Review.
https://doi.org/10.1007/s11912-021-01168-x 10.1182/blood-2016-03-643544 10.1182/blood-2011-04-347872 10.1182/blood-2010-05-282632 10.1111/j.1365-2141.2010.08541.x 10.1016/j.taap.2003.12.032 10.1002/ijc.2910430214 10.1038/sj.onc.1208968 10.1016/S0140-6736(99)05264-2 10.1038/ng.430 10.1038/ng.432 10.1038/ng.585 10.1002/ajim.22087 10.1007/s00204-016-1849-x 10.1007/BF02935915 10.1182/blood-2007-10-119974 10.1093/aje/kwi341 10.1002/pbc.26989 10.1111/jhn.12112 10.1200/JCO.2006.07.7792 10.1182/blood.V95.2.416 10.1111/j.1365-2141.2005.05735.x 10.1016/j.critrevonc.2017.03.020 10.1097/PAS.0b013e318213e90e 10.1111/bjh.12042 10.1016/S1470-2045(08)70314-0 10.1002/ajh.26144 10.1182/bloodadvances.2020001822 10.1200/JCO.2015.61.5385 10.1016/j.clml.2017.05.016 10.1016/j.jaad.2013.10.020 10.1007/s00277-011-1252-x 10.1182/blood.V122.21.839.839 10.1182/blood-2003-12-4428 10.1038/sj.leu.2403095 10.1200/JCO.1999.17.4.1244 10.1002/pbc.25607 10.1200/JCO.2008.21.1318 10.1200/JCO.1986.4.11.1628 10.3109/10428194.2011.616614 10.1093/annonc/mdt221 10.1182/blood-2002-01-0110 10.1182/blood.V124.21.370.370 10.1002/cncr.10552 10.1002/cncr.25008 10.1056/NEJMsa060185 10.1056/NEJMoa035091 10.1001/jama.297.11.1207 10.1001/jama.297.24.2705 10.1200/JCO.2007.10.8464 10.1002/pbc.24228 10.1080/10428194.2017.1326597 10.1200/JCO.2005.02.2707 10.1182/blood-2006-06-027714 10.1016/S1470-2045(09)70228-1 10.1056/NEJMoa0900386 10.1097/PPO.0b013e31826b1232 10.1111/bjh.15793 10.1002/pbc.25990 10.1002/pbc.28129 10.1016/j.bbmt.2005.07.001 10.3960/jslrt.56.28 10.1080/10428194.2016.1193860 10.12659/AOT.909122 10.1097/MD.0000000000011374 10.1038/s41409-018-0184-7 10.1038/s41598-020-78334-x 10.1007/s00277-020-04391-x 10.1182/blood-2019-131437 10.1002/ajh.25957 10.1038/s41375-019-0466-0 10.1158/1078-0432.CCR-19-4207 10.1038/s41375-019-0608-4 10.1056/NEJMoa1609783 10.1002/cncr.32116 10.1056/NEJMoa1709919 10.1182/blood-2011-01-329441 10.1182/blood-2006-11-056754 10.1111/bjh.13771 10.1200/JCO.20.00256 10.1200/JCO.2016.71.8585 10.1053/j.seminhematol.2020.11.004 10.1038/s41375-019-0548-z 10.1182/blood.2019000904 10.1038/s41375-019-0531-8 10.1038/s41375-018-0065-5 10.1200/JCO.2017.77.3648 10.1002/cncr.31848 10.1182/blood.2019001244 10.1111/bjh.17093 10.1182/blood-2016-09-738070 10.1016/S2352-3026(17)30208-9
Current Oncology Reports; Intermesoli T, Weber A et. al.

Jan 22nd, 2022 - Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-Hodgkin lymphoma variant virtually indistinguishable from acute lymphoblastic leukemia (ALL). We review the advancements in diagnostics, staging, treatment, and response assessment. T-L...

see more →

Guidelines  4 results

Management of adults and children receiving CAR T-cell therapy: 2021 best practice reco...
https://doi.org/10.1016/j.annonc.2021.12.003
Annals of Oncology : Official Journal of the European Soc... Hayden PJ, Roddie C et. al.

Dec 20th, 2021 - Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lympho...

Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelin...
https://doi.org/10.6004/jnccn.2020.0001
Journal of the National Comprehensive Cancer Network : JN... Brown P, Inaba H et. al.

Jan 8th, 2020 - Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved su...

NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
https://doi.org/10.6004/jnccn.2017.0147
Journal of the National Comprehensive Cancer Network : JN... Brown PA, Shah B et. al.

Sep 7th, 2017 - The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. H...

Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment...
https://doi.org/10.1016/j.bbmt.2011.12.585
Biology of Blood and Marrow Transplantation : Journal of ... Oliansky DM, Camitta B et. al.

Jan 3rd, 2012 - Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. T...

see more →

Drugs  121 results see all →

Clinicaltrials.gov  298 results

PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
https://clinicaltrials.gov/ct2/show/NCT02390752

Jan 19th, 2022 - Background Traditional therapeutic approaches to pediatric cancer have focused on cytotoxic agents and, more recently, targeted inhibition of cellular signaling pathways through the use of small molecule kinase inhibitors. Despite these interventi...

Optimizing PTCy Dose and Timing
https://clinicaltrials.gov/ct2/show/NCT03983850

Jan 18th, 2022 - Background: Post-transplantation cyclophosphamide (PTCy) reduces rates of severe acute and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation (HCT) and safely facilitates human leukocyte antigen (HLA)-hapl...

Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
https://clinicaltrials.gov/ct2/show/NCT05192889

Jan 14th, 2022 - This is a non-randomized phase I/II clinical trial. In Block I, all patients receiving common therapy evaluating the activity of combination chemotherapy with venetoclax and navitoclax in children with relapsed or refractory acute lymphoblastic le...

Venetoclax, Dasatinib, Prednisone, and Rituximab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT04872790

Jan 13th, 2022 - PRIMARY OBJECTIVES: I. Determine the maximum tolerated dose (MTD) and/or a recommended phase II dose (RP2D) of venetoclax in combination with dasatinib. II. Evaluate the safety of venetoclax in combination with dasatinib by assessing the frequency...

Optimal Methods of Disease Detection in Children and Young Adults With Acute Lymphoblastic Leukemia in the Pediatric Oncology Branch
https://clinicaltrials.gov/ct2/show/NCT03627208

Jan 13th, 2022 - Minimal residual disease detection in the bone marrow is highly prognostic for disease relapse in patients with acute lymphoblastic leukemia (ALL) and is determined based on a single bone marrow aspirate sample. Our anecdotal experience over the p...

see more →

News  901 results

Improved Survival in ALL Patients Who Relapse After Transplant
https://www.medscape.com/viewarticle/966558

Jan 13th, 2022 - A transplant offers a chance of a cure from leukemia, but when the transplant is not successful, such patients are left with few other options and a poor prognosis. But the management of such patients has been improving, and over the past 20 years...

Orca-T Shows Impressive Clinical Outcomes in High-Risk Hematological Cancers
https://www.onclive.com/view/orca-t-shows-impressive-clinical-outcomes-in-high-risk-hematological-cancers

Jan 4th, 2022 - The high-precision allogeneic cellular therapy Orca-T significantly improved graft-vs-host disease (GVHD)–free relapse-free survival (RFS) and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved ov...

NCCN Guidelines Set New Pace for Pediatric ALL
https://www.onclive.com/view/nccn-guidelines-set-new-pace-for-pediatric-all

Jan 3rd, 2022 - Patrick Brown, MD With the recent publication of an inaugural set of guidelines for treatment of pediatric acute lymphoblastic leukemia (ALL), the National Comprehensive Cancer Network (NCCN) seeks to introduce standards to a branch of care long ...

Examining the Development of T-cell Acute Lymphoblastic Leukemia
https://www.onclive.com/view/examining-the-development-of-t-cell-acute-lymphoblastic-leukemia

Dec 23rd, 2021 - T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive type of leukemia. Despite advances in treatments, patients have an extremely poor prognosis, highlighting the need to explore the genetic components that lead to the formation of T-ALL, ...

Novel Immunotherapy for Cancer Takes Cue From Transplant Rejection
https://www.medscape.com/viewarticle/964898

Dec 16th, 2021 - NEW YORK (Reuters Health) - A novel immunotherapy treatment works by triggering genetically modified T cells to reject cancer, much as they would a transplanted organ, researchers say. The approach was effective in mouse models and in leukemia cel...

see more →

Patient Education  1 results see all →